IDiyas

For the Inventor, By the Inventor

Fontaine-Bellenger, France

Patrick Rene Angibaud

USPTO Granted Patents = 30 

 

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 258(Granted Patents)


Location History:

  • Fontaine-Bellinger, FR (2017)
  • Fontaine-Bellenger, FR (1999 - 2018)
  • Issy-les-Moulineaux, FR (2021)
  • Saint Pierre d'Autils, FR (2018 - 2024)

Company Filing History:

goldMedal24 out of 2,076 
 
Janssen Pharmaceutica Nv
 patents
silverMedal5 out of 123 
 
Astex Therapeutics Limited
 patents
bronzeMedal1 out of 2 
 
Janssen-cilag S.a.
 patents

Years Active: 1999-2024

Loading Chart...
Loading Chart...
30 patents (USPTO):
1. 12084462 - Spiro bicyclic inhibitors of menin-MLL interaction (2024-09-10),
2. 11542247 - Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer (2023-01-03),
3. 11530226 - Azepane inhibitors of menin-MLL interaction (2022-12-20),
4. 11267804 - (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity (2022-03-08),
5. 11220517 - Spiro bicyclic inhibitors of menin-MLL interaction (2022-01-11),
6. 11155555 - Compounds (2021-10-26),
7. 10975100 - Fused bicyclic inhibitors of menin-MLL interaction (2021-04-13),
8. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),
9. 10611778 - Fused bicyclic inhibitors of menin-MLL interaction (2020-04-07),
10. 10526316 - Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors (2020-01-07),
11. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),
12. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),
13. 10045982 - Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors (2018-08-14),
14. 9636341 - Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase (2017-05-02),
15. 9598396 - Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors (2017-03-21),

Title: **Patrick Rene Angibaud: Innovator in Pharmaceutical Chemistry**

Introduction

Patrick Rene Angibaud is a prominent inventor based in Fontaine-Bellenger, France. With a remarkable portfolio of 30 patents, he has made significant contributions to the field of pharmaceutical chemistry, particularly in developing innovative therapeutic agents.

Latest Patents

Among his latest inventions are spiro bicyclic inhibitors of the menin-MLL interaction, which are pharmaceutical agents designed for therapy and prophylaxis in mammals. These compounds show promise in treating critical diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes. Another notable patent pertains to bi-heteroaryl substituted 1,4-benzodiazepines, which involve new derivative compounds that have potential applications in cancer treatment. These innovations not only enhance the existing therapies but also open doors for new treatments in oncology.

Career Highlights

Patrick has worked with leading companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Astex Therapeutics Limited. His experience in these organizations has allowed him to push the boundaries of drug development and contribute to meaningful advancements in medicine.

Collaborations

Throughout his career, Patrick has collaborated with notable colleagues such as Olivier Alexis Georges Querolle and Lieven Meerpoel. These collaborations have enriched his work and led to the creation of groundbreaking solutions in drug discovery.

Conclusion

Patrick Rene Angibaud's innovative approach and dedication to pharmaceutical research have resulted in critical advancements in therapeutic agents. His work continues to impact the medical field, offering hope for new and effective treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…